Comparative Pharmacology
Head-to-head clinical analysis: MONISTAT 7 COMBINATION PACK versus NYSTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONISTAT 7 COMBINATION PACK versus NYSTEX.
MONISTAT 7 COMBINATION PACK vs NYSTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miconazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, preventing conversion of lanosterol to ergosterol, thereby disrupting fungal cell membrane synthesis.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and lead to leakage of intracellular contents and cell death.
Intravaginal: one applicatorful (200 mg miconazole nitrate) at bedtime for 7 nights. Also: topical cream (2%) applied to affected area twice daily for 7 days.
Topical: Apply thin layer to affected area twice daily. Oral suspension (nystatin): 500,000-1,000,000 units (5-10 mL) four times daily for candidiasis. Vaginal tablets: 1 tablet (100,000 units) intravaginally once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours for miconazole after systemic absorption, reflecting slow tissue redistribution and hepatic clearance. After intravaginal administration, systemic absorption is minimal (<1.4%), so half-life is not clinically relevant.
Variable; estimated 2-5 hours for systemic absorption (if any), but negligible systemic levels due to poor absorption.
Miconazole is primarily metabolized in the liver; less than 1% of absorbed dose is excreted unchanged in urine. Fecal excretion accounts for approximately 50% of the dose, primarily as metabolites. Biliary excretion is minimal.
Primarily fecal (>95%) as unchanged drug; minimal renal excretion (<1%).
Category C
Category C
Antifungal
Antifungal